
Pfizer's New Lyme Vaccine Shows 70% Effectiveness in Trials
After more than 20 years without a Lyme disease vaccine in the U.S., Pfizer's new four-dose vaccine shows promising results that could protect millions from the most common tick-borne illness in America. The vaccine, tested across thousands of people in the U.S., Canada, and Europe, marks a hopeful step forward for outdoor enthusiasts and those living in high-risk areas.




%2Ffile%2Fattachments%2Forphans%2F2HIVVaccineResearch_437240.jpg)


